HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
HilleVax, Inc. (HLVX)
Company Research
Source: GlobeNewswire
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details: Date: Wednesday, February 7, 2024 Time: 2:00 – 2:25 p.m. Eastern Standard Time (EST)Moderator: Seamus FernandezLocation: St. Regis Hotel, New York, New York HilleVax Participant: Robert Hershberg, MD, PhD, Chairman and Chief Executive OfficerWebcast & Audio Visual: https://guggenheim.metameetings.net/events/guggenheimbiotech24/sessions/50246-hillevax-inc/webcast HilleVax is a clinical-stag
Show less
Read more
Impact Snapshot
Event Time:
HLVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HLVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HLVX alerts
High impacting HilleVax, Inc. news events
Weekly update
A roundup of the hottest topics
HLVX
News
- HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued Valuation [Seeking Alpha]Seeking Alpha
- HilleVax, Inc. (NASDAQ: HLVX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.MarketBeat
- HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress [Yahoo! Finance]Yahoo! Finance
- HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company ProgressGlobeNewswire
- Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) [Yahoo! Finance]Yahoo! Finance
HLVX
Earnings
- 3/20/24 - Beat
HLVX
Analyst Actions
- 3/21/24 - HC Wainwright
HLVX
Sec Filings
- 5/3/24 - Form 4
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- HLVX's page on the SEC website